Pulmonary Arterial Hypertension/ Parenchymal Lung Disease:
TITLE: A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects with Pulmonary Hypertension due to Parenchymal Lung Disease
PROTOCOL NO.: RIN-PH-201
This study is investigating a medicine called inhaled treprostinil (brand name Tyvaso®). In this form, inhaled treprostinil or placebo will be referred to as “study drug.” Placebo is made to look exactly like inhaled treprostinil but does not contain the active ingredient (treprostinil). Instead, it will pass through your body without affecting your symptoms of PH or any other body system. The study drug is given by inhaling (breathing in) the medicine into your lungs using a machine called a nebulizer (inhaling device). The nebulizer changes the medicine into a mist for you to breathe into your lungs.
Inhaled Treprostinil works by keeping the pulmonary arteries open and working properly so there is less strain on the heart.